NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals announced significant progress in its Q2 2026 financial results, including FDA review completion of its preservative-free ketamine ANDA with no major drug-related deficiencies, initiation of commercial manufacturing targeting 2026 launch, selection as prime contractor by DARPA for an FDA-approved Phase 2/3 trial of NRX-101 in co…